AR084366A1 - N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k - Google Patents

N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k

Info

Publication number
AR084366A1
AR084366A1 ARP110104779A ARP110104779A AR084366A1 AR 084366 A1 AR084366 A1 AR 084366A1 AR P110104779 A ARP110104779 A AR P110104779A AR P110104779 A ARP110104779 A AR P110104779A AR 084366 A1 AR084366 A1 AR 084366A1
Authority
AR
Argentina
Prior art keywords
alkyl
aminosulfonyl
carbamyl
independently selected
haloalkyl
Prior art date
Application number
ARP110104779A
Other languages
English (en)
Inventor
Eddy W Yue
Richard P Sparks
Yun Li
Andrew P Long-Combs
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR084366A1 publication Critical patent/AR084366A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

La presente proporciona derivados de N-(1-(fenil sustituido)etil)-9H-purin-6-aminas que modulan la actividad de fosfoinositida 3-quinasas (PI3Ks) y son de utilidad en el tratamiento de enfermedades relacionadas con la actividad de las PI3K incluyendo, por ejemplo, trastornos inflamatorios, trastornos de base inmune, cáncer y otras enfermedades.Reivindicación 1: Un compuesto de la fórmula (1) o una de sus sales farmacéuticamente aceptables; en donde: Ar es un resto de fórmula (2) ó (3); X es CH o N; Y es CH o N; R1 está seleccionado de alquilo C1-6, alquenilo C2-6, alquinilo C2-6 y haloalquilo C1-6 en donde dicho alquilo C1-6, alquenilo C2-6 y alquinilo C2-6 están cada uno opcionalmente sustituidos con 1, 2, 3 ó 4 grupos seleccionados, de modo independiente, de halo, OH, CN, NR1aR2b, alcoxi C1-6 y haloalcoxi C1-6; cada R1a y R2b está seleccionado, de modo independiente, de H y alquilo C1-6; o cualquier R1a y R2b junto con el átomo de N al que están unidos forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros, que está opcionalmente sustituido con 1, 2, 3 ó 4 sustituyentes seleccionados, de modo independiente, de alquilo C1-6; R2 está seleccionado de halo, CN, alquilo C1-6, haloalquilo C1-6, -L-(alquilo C1-6), -L-(haloalquilo C1-6) y -L-(alquilen C1-4)n-Cy2 y -(alquilen C1-4)n-Cy2; en donde dicho alquilo C1-6 en dicho alquilo C1-6 y -L-(alquilo C1-6) está opcionalmente sustituido con 1, 2, 3 ó 4 grupos R2a seleccionados de modo independiente; L es O, NRB, S, S(O), S(O)2, C(O), C(O)NRB, S(O)NRB, S(O)2NRB, NRBC(O), NRBS(O) y NRBS(O)2; RA y RB están seleccionados cada uno, de modo independiente, de H y alquilo C1-6; Cy2 está seleccionado de cicloalquilo C3-7, heterocicloalquilo de 4 - 7 miembros, fenilo y heteroarilo de 5 - 6 miembros; cada uno de los cuales está sustituido con p grupos R2a seleccionados de modo independiente; en donde p es 0, 1, 2, 3 ó 4; cada R2a está seleccionado, de modo independiente, de OH, NO2, CN, halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, amino, alquil C1-6-amino, di(alquil C1-6)amino, tio, alquil C1-6-tio, alquil C1-6-sulfinilo, alquil C1-6-sulfonilo, carbamilo, alquil C1-6-carbamilo, di(alquil C1-6)carbamilo, carboxi, alquil C1-6-carbonilo, alcoxi C1-6-carbonilo, alquil C1-6-carbonilamino, alquil C1-6-sulfonilamino, aminosulfonilo, alquil C1-6-aminosulfonilo, di(alquil C1-6)aminosulfonilo, aminosulfonilamino, alquil C1-6-aminosulfonilamino, di-(alquil C1-6)aminosulfonilamino, aminocarbonilamino, alquil C1-6-aminocarbonilamino y di(alquil C1-6) aminocarbonilamino; R3 es halo, CN, NO2, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, -(alquilen C1-4)r-Cy3, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb o S(O)2NRcRd; en donde dicho alquilo C1-6, alquenilo C2-6 y alquinilo C2-6 están cada uno opcionalmente sustituidos con 1, 2, 3 ó 4 grupos R3a seleccionados de modo independiente; Cy3 está seleccionado de cicloalquilo C3-7, heterocicloalquilo de 4 - 7 miembros, fenilo y heteroarilo de 5 - 6 miembros; cada uno de los cuales está opcionalmente sustituido con 1, 2, 3 ó 4 grupos R3a seleccionados de modo independiente; siempre que uno de los siguientes sea verdadero: (i) R3 es -(alquilen C1-4)r-Cy3; o (ii) R2 está seleccionado de -L-(alquilen C1-4)n-Cy2 y -(alquilen C1-4)n-Cy2 o (iii) R3 es -(alquilen C1-4)r-Cy3; y R2 está seleccionado de -L-(alquilen C1-4)n-Cy2 y -(alquilen C1-4)n-Cy2; cada R3a está seleccionado, de modo independiente, de halo, CN, NO2, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, cicloalquilo C3-7, heterocicloalquilo de 4 - 7 miembros, fenilo, heteroarilo de 5 - 6 miembros, (heterocicloalquilo de 4 - 7 miembros)-alquilo C1-4, fenil-alquilo C1-4, (heteroarilo de 5 - 6 miembros)-alquilo C1-4, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd y S(O)2NRcRd; en donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, heterocicloalquilo de 4 - 7 miembros, fenilo, heteroarilo de 5 - 6 miembros, (heterocicloalquilo de 4 - 7 miembros)-alquilo C1-4, fenil-alquilo C1-4 y (heteroarilo de 5 - 6 miembros)-alquilo C1-4 están cada uno opcionalmente sustituidos con 1, 2, 3 ó 4 grupos seleccionados, de modo independiente, de OH, NO2, CN, halo, alquilo C1-6, cianoalquilo C1-6, HO-alquilo C1-6, alcoxi C1-4-alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, amino, alquil C1-6-amino, di(alquil C1-6)amino, tio, alquil C1-6-tio, alquil C1-6-sulfinilo, alquil C1-6-sulfonilo, carbamilo, alquil C1-6-carbamilo, di(alquil C1-6)carbamilo, carboxi, alquil C1-6-carbonilo, alcoxi C1-6-carbonilo, alquil C1-6-carbonilamino, alquil C1-6-sulfonilamino, aminosulfonilo, alquil C1-6-aminosulfonilo, di(alquil C1-6)aminosulfonilo, aminosulfonilamino, alquil C1-6-aminosulfonilamino, di(alquil C1-6)aminosulfonilamino, aminocarbonilamino, alquil C1-6-aminocarbonilamino y di(alquil C1-6)aminocarbonilamino; R4 está seleccionado de H, OH. NO2, CN, halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, ciano-alquilo C1-6, HO-alquilo C1-6, alcoxi C1-4-alquilo C1-6, cicloalquilo C3-7, alcoxi C1-6, haloalcoxi C1-6, amino, alquil C1-6-amino, di(alquil C1-6)amino, tio, alquil C1-6-tio, alquil C1-6-sulfinilo, alquil C1-6-sulfonilo, carbamilo, alquil C1-6-carbamilo, di(alquil C1-6)carbamilo, carboxi, alquil C1-6-carbonilo, alcoxi C1-6-carbonilo, alquil C1-6-carbonilamino, alquil C1-6-sulfonilamino, aminosulfonilo, alquil C1-6-aminosulfonilo, di(alquil C1-6)aminosulfonilo, aminosulfonilamino, alquil C1-6-aminosulfonilamino, di(alquil C1-6)aminosulfonilamino, aminocarbonilamino, alquil C1-6-aminocarbonilamino y di(alquil C1-6)aminocarbonilamino; R5 está seleccionado de halo, OH, CN, alquilo C1-4, alcoxi C1-4 y haloalcoxi C1-4; cada Ra, Rc y Rd está seleccionado, de modo independiente, de H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, heterocicloalquilo de 4 - 7 miembros, fenilo, heteroarilo de 5 - 6 miembros, (heterocicloalquilo de 4 - 7 miembros)-alquilo C1-4, fenil-alquilo C1-4 y (heteroarilo de 5 - 6 miembros)-alquilo C1-4 en donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, heterocicloalquilo de 4 - 7 miembros, fenilo, heteroarilo de 5 - 6 miembros, (heterocicloalquilo de 4 - 7 miembros)-alquilo C1-4, fenil-alquilo C1-4 y (heteroarilo de 5 - 6 miembros)-alquilo C1-4 están sustituidos opcionalmente cada uno con 1, 2, 3, 4 ó 5 sustituyentes seleccionados, de modo independiente, de OH, NO2, CN, halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, ciano-alquilo C1-6, HO-alquilo C1-6, alcoxi C1-4-alquilo C1-6, cicloalquilo C3-7, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, amino, alquil C1-6-amino, di(alquil C1-6)amino, tio, alquil C1-6-tio, alquil C1-6-sulfinilo, alquil C1-6-sulfonilo, carbamilo, alquil C1-6-carbamilo, di(alquil C1-6)carbamilo, carboxi, alquil C1-6-carbonilo, alcoxi C1-6-carbonilo, alquil C1-6-carbonilamino, alquil C1-6-sulfonilamino, aminosulfonilo, alquil C1-6-aminosulfonilo, di(alquil C1-6)aminosulfonilo, aminosulfonilamino, alquil C1-6-aminosulfonilamino, di(alquil C1-6)aminosulfonilamino, aminocarbonilamino, alquil C1-6-aminocarbonilamino y di(alquil C1-6)aminocarbonilamino; cada Rb está seleccionado, de modo independiente, de alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, heterocicloalquilo de 4 - 7 miembros, fenilo, heteroarilo de 5 - 6 miembros, (heterocicloalquilo de 4 - 7 miembros)-alquilo C1-4, fenilalquilo C1-4 y (heteroarilo de 5 - 6 miembros)-alquilo C1-4; cada uno opcionalmente sustituido con 1, 2, 3, 4 ó 5 sustituyentes seleccionados, de modo independiente, de OH, NO2, CN, halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, ciano-alquilo C1-6, HO-alquilo C1-6, alcoxi C1-4-alquilo C1-6, cicloalquilo C3-7, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, amino, alquil C1-6-amino, di(alquil C1-6)amino, tio, alquil C1-6-tio, alquil C1-6- sulfinilo, alquil C1-6-sulfonilo, carbamilo, alquil C1-6-carbamilo, di(alquil C1-6)carbamilo, carboxi, alquil C1-6 carbonilo, alcoxi C1-6-carbonilo, alquil C1-6 carbonilamino, alquil C1-6-sulfonilamino, aminosulfonilo, alquil C1-6-aminosulfonilo, di(alquil C1-6)aminosulfonilo, aminosulfonilamino, alquil C1-6-aminosulfonilamino, di(alquil C1-6)aminosulfonilamino, aminocarbonilamino, alquil C1-6-aminocarbonilamino y di(alquil C1-6)aminocarbonilamino; cada Re está seleccionado, de modo independiente, de H, alquilo C1-4, CN, OH, alcoxi C1-4, alquil C1-4-sulfonilo, carbamilo, alquil C1-4-carbamilo, di(alquil C1-4)carbamilo y alquil C1-4-carbonilo; cada Rf está seleccionado, de modo independiente, de alquil C1-4-sulfonilo, alquil C1-4-carbonilo y alcoxi C1-4-carbonilo; n es 0 ó 1; y r es 0 ó 1.
ARP110104779A 2010-12-20 2011-12-19 N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k AR084366A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061425107P 2010-12-20 2010-12-20

Publications (1)

Publication Number Publication Date
AR084366A1 true AR084366A1 (es) 2013-05-08

Family

ID=45509664

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104779A AR084366A1 (es) 2010-12-20 2011-12-19 N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k

Country Status (8)

Country Link
US (3) US9096600B2 (es)
EP (2) EP2655374B1 (es)
JP (1) JP5961187B2 (es)
AR (1) AR084366A1 (es)
CA (1) CA2822070C (es)
ES (1) ES2764848T3 (es)
TW (1) TW201249844A (es)
WO (1) WO2012087881A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102030609B1 (ko) 2011-09-02 2019-10-11 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
US20150011569A1 (en) * 2011-12-15 2015-01-08 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
TWI736135B (zh) 2013-03-01 2021-08-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
US9790224B2 (en) 2013-06-07 2017-10-17 Rhizen Pharmaceuticals Sa Dual selective PI3 delta and gamma kinase inhibitors
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
KR20240153401A (ko) 2014-04-08 2024-10-22 인사이트 홀딩스 코포레이션 Ｊａｋ 및 ｐｉ3ｋ 억제제 조합에 의한 ｂ-세포 악성종양의 치료
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
DK3831833T3 (da) 2015-02-27 2022-11-14 Incyte Holdings Corp Fremgangsmåder til fremstillingen af en pi3k-inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP4086259A1 (en) 2015-11-06 2022-11-09 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
WO2017120194A1 (en) 2016-01-05 2017-07-13 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
AU2017241524B2 (en) 2016-03-28 2021-07-08 Incyte Corporation Pyrrolotriazine compounds as TAM inhibitors
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
CN108017641B (zh) * 2016-11-02 2021-01-05 深圳铂立健医药有限公司 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
TWI821200B (zh) 2017-09-27 2023-11-11 美商英塞特公司 Tam抑制劑之鹽
IL295978B2 (en) 2017-10-18 2024-01-01 Incyte Corp Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN119258070A (zh) 2018-06-01 2025-01-07 因赛特公司 治疗pi3k相关病症的给药方案
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
KR20210146287A (ko) * 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
JP2021008453A (ja) 2019-07-02 2021-01-28 エフェクター・セラピューティクス，インコーポレーテッド 翻訳阻害剤およびその使用
BR112022008858A2 (pt) 2019-11-08 2022-09-06 Revolution Medicines Inc Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CA3193554A1 (en) * 2020-10-06 2022-04-14 D.E. Shaw Research, Llc Lactam compounds as kv1.3 potassium shaker channel blockers
CN114773225B (zh) * 2022-05-09 2023-10-27 上海巽田科技股份有限公司 一种溴乙腈的制备方法
EP4658657A1 (en) * 2023-02-03 2025-12-10 Mirati Therapeutics, Inc. Substituted tricyclic compounds
US20250059175A1 (en) * 2023-08-15 2025-02-20 Prelude Therapeutics Incorporated Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals

Family Cites Families (285)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169967A (en) 1957-11-14 1965-02-16 Ciba Geigy Corp Methyl o-lower alkanoyl-reserpates
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
DE1770420U (de) 1958-02-27 1958-07-17 Tara Union G M B H Blumentopf aus kunststoff.
US3506643A (en) 1966-12-09 1970-04-14 Max Thiel N**6-aralkyl-adenosine derivatives
DE2139107A1 (de) 1971-08-04 1973-02-15 Merck Patent Gmbh Heterocyclisch substituierte adenosinverbindungen
US3814251A (en) 1972-08-09 1974-06-04 Sperry Rand Corp Power transmission
US3962443A (en) 1972-08-14 1976-06-08 Dainippon Pharmaceutical Co., Ltd. Antibacterial pharmaceutical compositions and processes for preparation thereof
DE2248232A1 (de) 1972-10-02 1974-04-11 Basf Ag 4-thiopyrimido eckige klammer auf 4,5-d eckige klammer zu pyrimidine
AR204003A1 (es) 1973-04-03 1975-11-12 Dainippon Pharmaceutical Co Procedimiento para preparar compuestos derivados del acido 2-(1-piperazinil)-5-oxopirido-(2,3-d)pirimidino-6-carboxilico y sus sales farmaceuticamente aceptables
US3862189A (en) 1973-08-14 1975-01-21 Warner Lambert Co Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents
US3936454A (en) 1973-08-14 1976-02-03 Warner-Lambert Company 5-Amino-4-chloro-6-(substituted amino)-pyrimidines
DK3375A (es) 1974-01-25 1975-09-15 Ciba Geigy Ag
JPS587626B2 (ja) 1974-02-13 1983-02-10 大日本製薬株式会社 ナフチリジン オヨビ キノリンユウドウタイノセイホウ
JPS50111080U (es) 1974-02-21 1975-09-10
JPS5625234Y2 (es) 1976-01-17 1981-06-15
JPS5359663U (es) 1976-10-25 1978-05-20
JPS5359663A (en) 1976-11-09 1978-05-29 Sumitomo Chem Co Ltd 2-halogeno methyl indole derivatives and process for praparation of the same
JPS52106897A (en) 1977-01-10 1977-09-07 Dainippon Pharmaceut Co Ltd Synthesis of piperazine derivatives
JPS5392767A (en) 1977-01-27 1978-08-15 Sumitomo Chem Co Ltd Preparation of 2-phthalimidomethylindole derivatives
JPS56123981U (es) 1980-02-20 1981-09-21
JPS56123981A (en) 1981-02-23 1981-09-29 Dainippon Pharmaceut Co Ltd Preparation of 1,4-disubstituted piperazine
JPS5883698A (ja) 1981-11-13 1983-05-19 Takeda Chem Ind Ltd キノン化合物およびその製造法
JPS5883698U (ja) 1981-11-27 1983-06-06 石川島播磨重工業株式会社 熱交換器
JPS58162949A (ja) 1982-03-20 1983-09-27 Konishiroku Photo Ind Co Ltd ハロゲン化銀カラ−写真感光材料
JPS6190153A (ja) 1984-10-09 1986-05-08 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JPS62103640A (ja) 1985-07-18 1987-05-14 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
JPS62103640U (es) 1985-12-18 1987-07-02
JPH07119970B2 (ja) 1986-04-18 1995-12-20 富士写真フイルム株式会社 画像形成方法
JPS6310746A (ja) 1986-07-01 1988-01-18 Tanabe Seiyaku Co Ltd ナフタレン誘導体
CA1324609C (en) 1986-07-30 1993-11-23 Eastman Kodak Company Photographic element and process
US4861701A (en) 1987-10-05 1989-08-29 Eastman Kodak Company Photographic element and process comprising a compound which comprises two timing groups in sequence
AT388372B (de) 1987-10-08 1989-06-12 Tanabe Seiyaku Co Neue naphthalinderivate und sie enthaltende pharmazeutika
JPH01250316A (ja) 1987-12-28 1989-10-05 Tanabe Seiyaku Co Ltd 抗脂血剤
EP0364598A4 (en) 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
US5208250A (en) 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
HU208124B (en) 1990-04-25 1993-08-30 Nissan Chemical Ind Ltd Process for producing pyridazinone derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
SU1712359A1 (ru) 1990-05-07 1992-02-15 Уфимский Нефтяной Институт Гидрохлорид 8 @ -гидроксихинолинового эфира 8-гидроксихинолин-7-карбоновой кислоты, в качестве бактерицида дл подавлени сульфатвосстанавливающих бактерий и культур РSеUDомоNаS и АRтнRовастеR
EP0464612B1 (en) 1990-06-28 1998-05-13 Fuji Photo Film Co., Ltd. Silver halide photographic materials
EP0481614A1 (en) 1990-10-01 1992-04-22 Merck & Co. Inc. Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
JPH04190232A (ja) 1990-11-26 1992-07-08 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
IL101860A0 (en) 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
JP3108483B2 (ja) 1991-09-30 2000-11-13 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
HUT64064A (en) 1992-02-13 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing puyrido/1,2-a/pyrimidine derivatives and pharmaceutical compositions comprising same as active ingredient
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO1993022291A1 (en) 1992-04-24 1993-11-11 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal aminopyrimidines
TW229140B (es) 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
FR2714907B1 (fr) 1994-01-07 1996-03-29 Union Pharma Scient Appl Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant.
US6342501B1 (en) 1994-02-25 2002-01-29 The Regents Of The University Of Michigan Pyrrolo[2,3-d] pyrimidines as antiviral agents
JPH0987282A (ja) 1995-09-21 1997-03-31 Kyowa Hakko Kogyo Co Ltd チアゾール誘導体
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
JPH09176116A (ja) 1995-12-27 1997-07-08 Toray Ind Inc 複素環誘導体およびその医薬用途
JPH1025294A (ja) 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
KR19990044383A (ko) 1996-07-03 1999-06-25 나가시마 카쭈시게, 노미야마 아키히코 신규 퓨린 유도체
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
JPH10231297A (ja) 1997-02-20 1998-09-02 Japan Energy Corp 新規なアデニン−１−ｎ−オキシド誘導体およびその医薬用途
WO1999024432A1 (fr) 1997-11-12 1999-05-20 Mitsubishi Chemical Corporation Derives de purine et medicament les renfermant en tant qu'ingredient actif
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
KR20010041346A (ko) 1998-02-25 2001-05-15 브루스 엠. 에이센, 토마스 제이 데스로저 포스포리파제 ａ2 억제제
EA200000868A1 (ru) 1998-02-25 2001-04-23 Дженетикс Инститьют, Инк. Ингибиторы фосфолипаз
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
CN1151127C (zh) 1998-05-04 2004-05-26 Asta药物股份公司 吲哚衍生物及其用于治疗恶性肿瘤和其它基于病理细胞增生的疾病的用途
WO1999061436A1 (en) 1998-05-26 1999-12-02 Chugai Seiyaku Kabushiki Kaisha Heterocyclic indole derivatives and mono- or diazaindole derivatives
JP3997651B2 (ja) 1998-06-24 2007-10-24 コニカミノルタホールディングス株式会社 新規色素及び画像記録材料及び感熱転写材料及びインクジェット記録液
WO2000009495A1 (en) 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
ATE256677T1 (de) 1998-08-25 2004-01-15 Uab Research Foundation Inhibitoren der bakteriellen nad synthetase
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
WO2000044750A1 (en) 1999-02-01 2000-08-03 Cv Therapeutics, Inc. PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a)
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
JP2000281654A (ja) 1999-03-26 2000-10-10 Tanabe Seiyaku Co Ltd イソキノリン誘導体
DE19932571A1 (de) 1999-07-13 2001-01-18 Clariant Gmbh Verfahren zur Herstellung von Biarylen unter Palladophosphacyclobutan-Katalyse
JP2001151771A (ja) 1999-09-10 2001-06-05 Kyowa Hakko Kogyo Co Ltd 含窒素芳香族複素環誘導体
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
EP1138328A1 (en) 2000-03-29 2001-10-04 Eli Lilly And Company Limited Naphthalene derivatives as CNS drugs
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
DE60105023T2 (de) 2000-06-28 2005-08-18 Smithkline Beecham P.L.C., Brentford Nassvermahlungsverfahren
CN1331340A (zh) 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人拓扑异构酶12.1和编码这种多肽的多核苷酸
WO2002002533A1 (en) 2000-07-05 2002-01-10 Yamanouchi Pharmaceutical Co., Ltd. Propane-1,3-dione derivatives
FR2814073B1 (fr) 2000-09-21 2005-06-24 Yang Ji Chemical Company Ltd Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux derives de l'indole a titre de principes actifs d'une telle composition
DOP2002000334A (es) 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
CZ20032332A3 (cs) 2001-03-01 2003-11-12 Shionogi & Co., Ltd. Heteroarylové sloučeniny obsahující dusík, které mají inhibiční aktivitu proti HIV integrase
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
JP2004525150A (ja) 2001-03-30 2004-08-19 スミスクライン ビーチャム コーポレーション 治療用化合物としてのピラゾロピリジン類の使用
JP4237497B2 (ja) 2001-03-30 2009-03-11 スミスクライン ビーチャム コーポレーション ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用
EP1385847B1 (en) 2001-04-27 2005-06-01 SmithKline Beecham Corporation Pyrazolo[1,5-a]pyridine derivatives
CZ294535B6 (cs) 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
MXPA04002243A (es) 2001-09-19 2004-06-29 Aventis Pharma Sa Compuestos quimicos.
KR20040041177A (ko) 2001-09-26 2004-05-14 바이엘 파마슈티칼스 코포레이션 당뇨병 치료제로서의 1,6-나프티리딘 유도체
WO2003029209A2 (en) 2001-10-02 2003-04-10 Smithkline Beecham Corporation Chemical compounds
CN101703509A (zh) 2001-10-30 2010-05-12 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
CA2465090C (en) 2001-11-09 2010-02-02 Enzon, Inc. Polymeric thiol-linked prodrugs employing benzyl elimination systems
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
JP4391825B2 (ja) 2001-12-06 2009-12-24 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
ATE372341T1 (de) 2001-12-06 2007-09-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
TW200301135A (en) 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
AU2003211931A1 (en) 2002-02-13 2003-09-04 Takeda Chemical Industries, Ltd. Jnk inhibitor
WO2003074497A1 (en) 2002-03-01 2003-09-12 Pintex Pharmaceutical, Inc. Pin1-modulating compounds and methods of use thereof
AU2003222106A1 (en) 2002-04-03 2003-10-20 Bristol-Myers Squibb Company Thiopene-based tricyclic compounds and pharmaceutical compositions comprising same
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
DE60322920D1 (de) 2002-08-13 2008-09-25 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase-hemmender wirkung
JP4190232B2 (ja) 2002-08-26 2008-12-03 富士通株式会社 機械研磨を行う方法
TWI349671B (en) 2002-09-27 2011-10-01 Dainippon Sumitomo Pharma Co Novel adenine derivative and its use
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
ES2412273T3 (es) 2002-11-21 2013-07-10 Novartis Ag Inhibidores de 2-morfolín-4-pirimidinas como inhibidores de fosfotidilinositol (PI) 3-quinasa y su uso en el tratamiento del cáncer.
WO2004048326A1 (ja) 2002-11-25 2004-06-10 Mochida Pharmaceutical Co., Ltd. ４−ヒドロキシピペリジン誘導体を有効成分とする呼吸器疾患治療剤
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004058682A1 (ja) 2002-12-26 2004-07-15 Eisai Co., Ltd. 選択的エストロゲン受容体モジュレーター
CZ294538B6 (cs) 2002-12-30 2005-01-12 Ústav Experimentální Botaniky Akademie Vědčeské Re Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
RU2233842C1 (ru) 2003-01-13 2004-08-10 Петров Владимир Иванович Производные пурина, обладающие противовирусной активностью
PE20050068A1 (es) 2003-02-06 2005-03-11 Novartis Ag 2-cianopirrolopirimidinas como inhibidores de la catepsina s
GB0304640D0 (en) 2003-02-28 2003-04-02 Novartis Ag Organic compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
SE0300908D0 (sv) 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
JP2007501272A (ja) 2003-05-05 2007-01-25 ニューロジェン・コーポレーション 置換イミダゾロピラジンおよびトリアゾロピラジン誘導体類：ｇａｂａａレセプタリガンド類
WO2004113335A2 (en) 2003-06-20 2004-12-29 Chiron Corporation Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
JP4570015B2 (ja) 2003-07-14 2010-10-27 クミアイ化学工業株式会社 ２−イソオキサゾリン誘導体及びそれを有効成分として含有する除草剤
US20050124637A1 (en) 2003-08-15 2005-06-09 Irm Llc Compounds and compositions as inhibitors of receptor tyrosine kinase activity
EP2145888A1 (en) 2003-09-18 2010-01-20 Conforma Therapeutics Corporation Deazapurine derivatives as HSP90-Inhibitors
WO2005046578A2 (en) 2003-09-23 2005-05-26 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
EP1717238A4 (en) 2004-02-16 2008-03-05 Daiichi Seiyaku Co FUNGICIDES HETEROCYCLIC COMPOUNDS
CN1560035A (zh) 2004-03-12 2005-01-05 沈阳药科大学 5－羟基吲哚－3－羧酸脂类衍生物
WO2005091857A2 (en) 2004-03-12 2005-10-06 Bayer Pharmaceuticals Corporation 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders
JPWO2005092892A1 (ja) 2004-03-26 2008-02-14 大日本住友製薬株式会社 ８−オキソアデニン化合物
AU2005231440B9 (en) 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
PL1761540T3 (pl) 2004-05-13 2017-06-30 Icos Corporation Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
EP1773830A1 (en) 2004-07-22 2007-04-18 AstraZeneca AB Fused pyrimidones useful in the treatment and the prevention of cancer
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
KR20070072598A (ko) 2004-10-19 2007-07-04 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 인돌 및 벤지미다졸 유도체
WO2006052546A2 (en) 2004-11-04 2006-05-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
BRPI0517887A (pt) 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
EP1885356A2 (en) 2005-02-17 2008-02-13 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
ATE474829T1 (de) 2005-06-27 2010-08-15 Amgen Inc Entzündungshemmende arylnitrilverbindungen
FR2889192A1 (fr) 2005-07-27 2007-02-02 Cytomics Systems Sa Composes antifongiques, compositions contenant ces composes et leurs utilisations
BRPI0614801A2 (pt) 2005-08-16 2009-05-19 Genzyme Corp compostos de ligação a receptor de quimiocina
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
JPWO2007034817A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
NZ567851A (en) 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
EP1783114A1 (en) 2005-11-03 2007-05-09 Novartis AG N-(hetero)aryl indole derivatives as pesticides
WO2007059108A2 (en) 2005-11-10 2007-05-24 Chemocentryx, Inc. Substituted quinolones and methods of use
TWI630207B (zh) 2005-12-13 2018-07-21 英塞特控股公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US20100227880A1 (en) 2006-01-25 2010-09-09 Kristjan Gudmundsson Chemical compounds
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
WO2007102392A1 (ja) 2006-03-03 2007-09-13 Shionogi & Co., Ltd. Ｍｍｐ－１３選択的阻害剤
JP2009531443A (ja) 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制
KR101499783B1 (ko) 2006-04-04 2015-03-09 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
US20080004253A1 (en) 2006-06-30 2008-01-03 Bryan James Branstetter Thiazolopyrimidine modulators of TRPV1
US20080009508A1 (en) 2006-07-10 2008-01-10 Lucie Szucova 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin
US20100035756A1 (en) 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
BRPI0714908B8 (pt) 2006-08-08 2021-05-25 Chugai Pharmaceutical Co Ltd derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
SG174086A1 (en) 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
EP1972631A1 (en) 2007-03-23 2008-09-24 Novartis AG Imidazopyridazines as PI3K lipid kinase inhibitors
US20080114007A1 (en) 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
SG178786A1 (en) 2006-11-13 2012-03-29 Lilly Co Eli Thienopyrimidinones for treatment of inflammatory disorders and cancers
KR101532256B1 (ko) 2006-11-22 2015-06-29 인사이트 코포레이션 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
CA2672960A1 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
DK2125827T3 (da) 2006-12-29 2010-12-20 Hoffmann La Roche Azaspiroderivater
AR065194A1 (es) 2007-02-05 2009-05-20 Xenon Pharmaceuticals Inc Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio
EP2134683A2 (en) 2007-02-12 2009-12-23 Intermune, Inc. Novel inhibitors hepatitis c virus replication
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
AU2008231304B2 (en) 2007-03-23 2011-05-12 Amgen Inc. Heterocyclic compounds and their uses
EP2132207A2 (en) 2007-03-23 2009-12-16 Amgen Inc. Heterocyclic compounds and their uses
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
JP2010531304A (ja) 2007-06-18 2010-09-24 ユニバーシティ オブ ルイビル リサーチ ファウンデーション、インコーポレイテッド 抗悪性腫瘍活性を有するｐｆｋｆｂ３阻害物質ファミリー
JP5395068B2 (ja) 2007-06-29 2014-01-22 ギリアード サイエンシーズ， インコーポレイテッド トール様受容体７の調節物質としてのプリン誘導体およびその使用
US20090053192A1 (en) 2007-08-10 2009-02-26 Burnham Institute For Medical Research Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
JP2009076865A (ja) 2007-08-29 2009-04-09 Fujifilm Corp 有機電界発光素子
WO2009034386A1 (en) 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
JP2009080233A (ja) 2007-09-26 2009-04-16 Kyocera Mita Corp 電子写真感光体
CZ300774B6 (cs) 2007-10-05 2009-08-05 Univerzita Palackého Substituované 6-(alkylbenzylamino)purinové deriváty pro použití jako antagonisté cytokininových receptoru a prípravky obsahující tyto slouceniny
AU2008323694A1 (en) 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
WO2009063235A1 (en) 2007-11-13 2009-05-22 Astrazeneca Ab Derivatives of 1,9-dihydro-6h-purin-6-one and uses thereof-018
JP2009120686A (ja) 2007-11-14 2009-06-04 Toyo Ink Mfg Co Ltd 光重合開始剤、重合性組成物、および重合物の製造方法。
CL2008003798A1 (es) 2007-12-19 2009-10-09 Amgen Inc Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
US8399483B2 (en) 2007-12-21 2013-03-19 Ucb Pharma S.A. Quinoxaline and quinoline derivatives as kinase inhibitors
US20110112135A1 (en) 2007-12-21 2011-05-12 Singhaus Jr Robert Ray Imidazo [1,2-A] Pyridine Compounds
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US7960397B2 (en) 2007-12-28 2011-06-14 Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions
US8410098B2 (en) 2007-12-28 2013-04-02 Topharman Shanghai Co., Ltd. N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)sulfonylphenyl)-4,5-dihydro-5-OXO-1,2,4-triazin-6-yl]ethyl}butyramide, the preparation method and use thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009098715A2 (en) 2008-01-11 2009-08-13 Natco Pharma Limited Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
ES2494365T3 (es) 2008-01-30 2014-09-15 Genentech, Inc. Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
EP2444403A1 (en) 2008-04-18 2012-04-25 Shionogi Co., Ltd. Heterocyclic compound having inhibitory activity on PI3K
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
WO2009140215A2 (en) 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
WO2009151972A1 (en) 2008-05-28 2009-12-17 , The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Materiel Command Small molecule inhibitors of botulinum neurotoxins
CN102203074A (zh) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 芳基gpr119激动剂及其用途
US8026271B2 (en) 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
NZ631024A (en) 2008-11-13 2016-04-29 Gilead Calistoga Llc Therapies for hematologic malignancies
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
SG172301A1 (en) 2008-12-24 2011-07-28 Bial Portela & Ca Sa Pharmaceutical compounds
EP2387575B1 (en) 2009-01-15 2013-09-04 Anvyl, LLC Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
US8513284B2 (en) 2009-02-13 2013-08-20 Ucb Pharma, S.A. Fused pyridine and pyrazine derivatives as kinase inhibitors
EP2414044A1 (en) 2009-03-31 2012-02-08 ArQule, Inc. Substituted indolo-piperidine compounds
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
PT2421536E (pt) 2009-04-20 2015-10-20 Gilead Calistoga Llc Métodos de tratamento para tumores sólidos
WO2010127208A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
UY32743A (es) 2009-06-25 2010-12-31 Amgen Inc Compuestos heterocíclicos y sus usos
US8754089B2 (en) 2009-06-25 2014-06-17 Amgen Inc. Heterocyclic compounds and their uses
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CR20170071A (es) 2009-06-29 2017-03-28 Agios Pharmaceuticals Inc Compuestos terapeuticos y composiciones
EP2456443A1 (en) 2009-07-21 2012-05-30 Gilead Calistoga LLC Treatment of liver disorders with pi3k inhibitors
AR077974A1 (es) 2009-08-28 2011-10-05 Takeda Pharmaceutical Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
AU2010309882B2 (en) 2009-10-20 2016-01-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
CN102666541B (zh) 2009-10-22 2015-11-25 吉里德科学公司 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物
PT2496567T (pt) 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
CN102695708B (zh) 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
EP2499126B1 (en) 2009-11-12 2015-01-07 UCB Pharma, S.A. Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors
WO2011058111A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Aminopurine derivatives as kinase inhibitors
WO2011069294A1 (zh) 2009-12-10 2011-06-16 中国医学科学院药物研究所 N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2513109A1 (en) 2009-12-18 2012-10-24 Amgen Inc. Heterocyclic compounds and their uses
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
US8633183B2 (en) 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
EP3050882B1 (en) 2010-03-10 2018-01-31 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US20130203778A1 (en) 2010-03-22 2013-08-08 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a pyrimidineone derivative
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
EP2579878A1 (en) 2010-06-11 2013-04-17 Gilead Calistoga LLC Methods of treating hematological disorders with quinazolinone compounds in selected patients
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
MX2012014996A (es) 2010-07-01 2013-03-21 Amgen Inc Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
EP2588467A1 (en) 2010-07-01 2013-05-08 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
US20130096134A1 (en) 2010-07-02 2013-04-18 Amgen Inc. Heterocyclic compounds and their uses
US20130324561A1 (en) 2010-09-24 2013-12-05 Gilead Calistroga Llc. Atropisomers of p13k-inhibiting compounds
CA2815445A1 (en) 2010-11-04 2012-05-10 Amgen Inc. 5 -cyano-4, 6 -diaminopyrimidine or 6 -aminopurine derivatives as pi3k-delta inhibitors
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2012068343A1 (en) 2010-11-17 2012-05-24 Amgen Inc. Quinoline derivatives as pik3 inhibitors
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
AU2011349669A1 (en) 2010-12-23 2013-07-11 Amgen Inc. Heterocyclic compounds and their uses
KR20180080358A (ko) 2011-01-10 2018-07-11 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
AU2012212323A1 (en) 2011-02-01 2013-09-12 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
KR102030609B1 (ko) 2011-09-02 2019-10-11 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
CN104024257A (zh) 2011-10-04 2014-09-03 吉利德卡利斯托加有限责任公司 Pi3k的新的喹喔啉抑制剂
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
AU2013337824B2 (en) 2012-11-01 2018-03-08 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
SMT202100040T1 (it) 2013-05-17 2021-03-15 Incyte Corp Derivati di bipirazolo come inibitori di jak
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
DK3831833T3 (da) 2015-02-27 2022-11-14 Incyte Holdings Corp Fremgangsmåder til fremstillingen af en pi3k-inhibitor
WO2016183062A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor

Also Published As

Publication number Publication date
WO2012087881A1 (en) 2012-06-28
US20170158696A1 (en) 2017-06-08
US20120157430A1 (en) 2012-06-21
ES2764848T3 (es) 2020-06-04
US9527848B2 (en) 2016-12-27
EP2655374A1 (en) 2013-10-30
JP5961187B2 (ja) 2016-08-02
US9815839B2 (en) 2017-11-14
EP3660016A1 (en) 2020-06-03
CA2822070C (en) 2019-09-17
CA2822070A1 (en) 2012-06-28
US20150284390A1 (en) 2015-10-08
EP2655374B1 (en) 2019-10-23
US9096600B2 (en) 2015-08-04
TW201249844A (en) 2012-12-16
JP2014500324A (ja) 2014-01-09

Similar Documents

Publication Publication Date Title
AR084366A1 (es) N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
AR081823A1 (es) DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
AR066879A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
AR067413A1 (es) Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
AR090548A1 (es) Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR087591A1 (es) Derivados de ciclohexil azetidina como inhibidores de jak
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR070136A1 (es) Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa
AR086539A1 (es) COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE
AR060438A1 (es) 2-(piridin-2-il) - pirimidinas como fungicidas.
AR097431A1 (es) Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR051195A1 (es) Piridinas como inhibidores de plk
PE20141973A1 (es) Compuestos de heterociclilo como inhibidores de mek
MX381849B (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.
AR088218A1 (es) Compuestos heterociclicos utiles como inhibidores de pi3k
AR077468A1 (es) Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
AR072518A1 (es) Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met."
NI200900032A (es) Compuestos de pirido (2, 3-d) pirimidinonay su uso como inhibidores de pi3
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR085316A1 (es) Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas
AR061642A1 (es) Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk

Legal Events

Date Code Title Description
FA Abandonment or withdrawal